Part 5/7:
However, this commercial has also stirred controversy. An open letter from a pharma industry group expressed concerns over Hims' advertising practices, describing the ad as irresponsible and misleading. They argue that the compounded solutions promoted are not FDA-approved, challenging Hims' credibility. While these criticisms raise valid points on health marketing practices, they also highlight the fear and apprehension within big pharmaceutical companies regarding Hims' growth and potential market share.